We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

By LabMedica International staff writers
Posted on 10 Sep 2025

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. More...

Traditional systems for isolating circulating tumor cells (CTCs) vary in efficiency and are limited by size or marker-based restrictions. Now, a new approach has demonstrated the ability to isolate not only tumor cells but also cancer-associated fibroblasts, significantly enhancing diagnostic accuracy and treatment monitoring.

Researchers at the Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, South Korea), along with collaborators, have developed an automated platform known as CTCeptor. Unlike existing FDA-approved systems that rely on markers or size-based methods, this hemocyte extraction–based technology captures tumor cells of different sizes and markers. Importantly, it can also isolate cancer-associated fibroblasts (cCAFs), which are critical players in the tumor microenvironment.

The study compared three FDA-approved automated CTC isolation systems (marker-based, size-based, and hemocyte extraction–based) based on the same blood samples of early-stage breast cancer patients. Their comparison of CTCeptor with CellSearch and Parsortix showed that CTCeptor detected at least 15 times more CTCs than competing technologies and identified cCAFs at a frequency about 10 times higher than tumor cells. The findings, published in Analytical Chemistry, also demonstrated stable recovery rates across breast, lung, and ovarian cancer cell lines, regardless of EpCAM expression or cell size.

By capturing both CTCs and fibroblasts, CTCeptor offers a more comprehensive picture of the tumor microenvironment. This could improve early cancer diagnosis, refine treatment monitoring, and enhance the success rate of drug development. The ability to analyze tumor and microenvironment cells from a single blood sample makes this technology a powerful tool for advancing precision oncology and personalizing treatment strategies.

“Although liquid biopsy technology has focused on obtaining cancer information from blood for the past 25 years, this study holds significance, as it serves as the basis for identifying not only cancer but also key information about the tumor microenvironment,” said DGIST Professor Minseok Kim, lead author of the study. “Our technology can simultaneously analyze tumor cells and microenvironment cells with a single blood sample, which will greatly contribute to increasing the success rate of new drug development and establishing personalized treatment strategies.”

Related Links:
DGIST


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The novel approach could improve early cancer detection (Photo courtesy of AdobeStock)

Simple Blood Test Offers Non-Invasive Alternative for Early Colon Cancer Detection

Colorectal cancer remains one of the leading causes of cancer-related deaths, and early detection is critical for improving patient outcomes. Current methods, such as colonoscopy, are effective but invasive... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.